Medical and Regulatory Affairs
Life Science Leader – Orphan Drug Incentives & Innovations On The Rise
The year 2015 was a productive one for introduction of drugs that target rare diseases. U.S. regulators approved 21 new orphan drugs, a 40 percent increase from the previous year. European regulators approved a record 18 orphan compounds, a small increase over 2014. Any progress is a good thing, but these advances pale when weighed...